The Multiple Myeloma Channel is supported with funding from BMS (Gold) and Legend Biotech (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASCO 2024 | Cilta-cel versus SoC in functionally high-risk myeloma with one prior therapy
Luciano Costa, MD, PhD, UAB School of Medicine, Birmingham, AL, discusses a subgroup analysis of the CARTITUDE-4 trial (NCT04181827), comparing ciltacabtagene autoleucel (cilta-cel) to standard-of-care (SoC) regimens in patients with multiple myeloma (MM) with one prior line of therapy. The analysis showed a significant benefit of cilta-cel, especially in patients with functionally high-risk disease, with comparable safety between the two groups. This interview took place during the 2024 American Society of Clinical Oncology (ASCO) Meeting in Chicago, IL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
